Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022

Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021–February 2022

Mircea T. Sofonea, Bénédicte Roquebert, Vincent Foulongne, David Morquin, Laura Verdurme, Sabine Trombert-Paolantoni, Mathilde Roussel, Jean-Christophe Bonetti, Judith Zerah, Stéphanie Haim-Boukobza, and Samuel AlizonComments to Author 
Author affiliations: Université de Montpellier, Montpellier, France (M.T. Sofonea); Laboratoire Cerba, Saint Ouen L’Aumône, France (B. Roquebert, L. Verdurme, S. Trombert-Paolantoni, M. Roussel, S. Haim-Boukobza); Centre Hospitalier Universitaire de Montpellier, Montpellier (V. Foulongne, D. Morquin); Laboratoire Cerballiance Paris et Île-de-France Est, Paris, France (J.-C. Bonetti, J. Zerah); Centre National de la Recherche Scientifique, Paris (S. Alizon)

Main Article

Table 1

Main characteristics of SARS-CoV-2 variant-specific screening tests (N = 131,478), France, September 1–December 18, 2021*

Characteristic Value
Age of patient, y, median (95% CI)
36 (6–74)
TIB Molbiol 4,887 (3.7)
PerkinElmer 33,037 (25.1)
ID Solutions (Evolution)
93,554 (71.2)
General population 127,337 (96.9)
4,141 (3.1)
Ile-de-France 51,407 (39.1)
Hauts-de-France 16,938 (12.9)
Normandie 11,996 (9.1)
Nouvelle-Aquitaine 8,516 (6.5)
Provence-Alpes-Côte d’Azur 7,549 (5.7)
Occitanie 7,143 (5.4)
Corse 5,528 (4.2)
Bourgogne-Franche-Comté 5,155 (3.9)
Grand Est 5,136 (3.9)
Centre-Val de Loire 4,811 (3.7)
Bretagne 3,455 (2.6)
1,296 (0.9)
A0B0C1 101,970 (77.6)
A0B0C0 6,969 (5.3)
A0B1C1 899 (0.68)
A1B0C1 37 (<0.1)
A1B0C0 15 (<0.1)
Other 21,588 (16.4)

*Values are no. (%) patients except as indicated.

Main Article

Page created: May 03, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.